China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the clinical trial approval and research and development (R&D) materials of 18F-APN-1607, a Tau protein positron photography tracer used for PET imaging diagnosis, from Japan’s Aprinoia Therapeutics Inc. and Aprinoia Therapeutics Suzhou, along with exclusive clinical development, manufacturing, and marketing rights in mainland China.
Transaction Details
Dongcheng Pharma will pay Aprinoia Japan USD 8 million in cash and Aprinoia Suzhou RMB 14 million (USD 2 million) in upfront payments, and is committed to USD 2 million in milestone payments and sales commission.
18F-APN-1607: Mechanism and Potential Applications
18F-APN-1607, a preparation that can specifically combine with Tau protein accumulated in the brain to diagnose Alzheimer’s disease (AD), can also potentially be used to detect non-AD Tau-related diseases, such as progressive supranuclear palsy (PSP), cortical basal ganglia degeneration (CBD), and others.-Fineline Info & Tech
